Laboratory Purists and Renegade Empiricists Duke It Out Over How to Proceed with Vaccine Development Efforts Current Products ‘Certain to Fail’ Although significant scientific hurdles continue to impede progress toward the development of an ideal HIV vaccine candidate, a number…
As All the World Drools Over Triple HAART Hype, Low Key Dual Combo Appears First to Achieve the Unimaginable The first cure? In a recent issue of Nature Medicine, a group of immunologists make two obvious but rarely discussed observations…
Infectious HIV Persists After Up to 2 1/2 Years of Triple Drug Therapy, Due to a Non-Decaying 3rd Compartment Its the immune system after all. Can HIV be eradicated from a human host? Can currently available combination therapy approaches eliminate…
Just When You Thought the Global HIV/AIDS Picture Couldn't Get Any Worse -- It Did What could a vaccine do? As people in the North America, Western Europe and Australia begin to live longer with HIV and AIDS (and even…
David Ho proposes immunotherapeutic vaccination to help the immune system clear the long-lived "3rd" compartment of HIV-infected cells. These latently infected CD4+ T-cells with integrated HIV DNA currently represent the greatest obstacle to the potential eradication of HIV infection. And…
Three New Antivirals Trickle From the Pipeline, But Will They Provide Any Benefit for Those Who Need Them Most? Whose needs served? A group of new anti-HIV therapies are about to enter expanded access programs, but heavily pre-treated patients aren't…
The FDA's Oncologic Drug Advisory Committee Decides the Fate of Two Drugs for AIDS-Related Malignancies ‘Nowhere near bowled over’ On June 23rd, the FDA's Oncologic Drug Advisory Committee held a hearing to determine the fate of Bristol Myers-Squibb's supplemental new…
Republicans and Pharmaceutical Industry Target the FDA in a Dangerous Plan to Undermine the FDA ‘Two lone voices’ Gregg Gonsalves, TAG's Policy Director and Washington watchdog, has just returned from a week in our nation's capitol, on the heels of…
Data from the 23rd ACTG Meeting Document Reduction in Number of Opportunistic Infections in the Era of HAART ‘It’s a good thing’ Since the approval and wide-spread use of protease inhibitors in mid-1996, AIDS clinicians and primary care physicians across…
Having Temporarily Suspended Disbelief, Would-Be Eradicatee Looks Forward to Still Uncertain Future ‘A perilous seduction’ Irrational exuberance might not be the sole domain of streets Broad and Wall. Speculation in AIDS futures has also seen quite a run over the…